NIH PA · NIH · R44
PA-27-101: NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The NIH Phase IIB Strategic Breakthrough award bridges the funding gap between the end of a Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II award and commercialization. The Phase IIB Strategic Breakthrough provides previously funded NIH SBIR or STTR projects additional support for later-stage research and development (R&D).
- NOFO number
- PA-27-101
- Type
- PA
- Activity code
- R44
- Primary institute
- NIH
- Clinical trials
- Optional
- Posted
- May 28, 2026
- Opens
- Aug 5, 2026
- Expires
- Apr 6, 2029
PA-27-101 due dates
8 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| Not Applicable | September 05, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| Not Applicable | January 05, 2027 * | Not Applicable | March 2027 | May 2027 | July 2027 |
| Not Applicable | April 05, 2027 * | Not Applicable | July 2027 | August 2027 | December 2027 |
| Not Applicable | September 05, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| Not Applicable | January 05, 2028 * | Not Applicable | March 2028 | May 2028 | July 2028 |
| Not Applicable | April 05, 2028 * | Not Applicable | July 2028 | August 2028 | December 2028 |
| Not Applicable | September 05, 2028 * | Not Applicable | November 2028 | January 2029 | April 2029 |
| Not Applicable | January 05, 2029 * | Not Applicable | March 2029 | May 2029 | July 2029 |
| Not Applicable | April 05, 2029 * | Not Applicable | July 2029 | August 2029 | December 2029 |
What its predecessor PA-24-245 funded
PA-27-101 reissues PA-24-245. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 789 projects and $650.9M in FY2022–FY2026.
Projects funded
789
Distinct projects, FY2022–FY2026
New awards
674
Type 1 (new project) award records
NIH funding
$650.9M
Award dollars under PA-24-245, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 359 | 303 | $234.1M |
| FY2026 | 595 | 371 | $416.9M |
Institutions with the most funding
- Mucommune, LLC$11.6M · 8 projects
- Innovative Design Labs, Inc.$7.8M · 5 projects
- Epicypher, Inc.$6.7M · 4 projects
- Gentibio, Inc.$4.7M · 4 projects
- Hesperos, Inc$4.7M · 3 projects
- Trethera Corporation$4.7M · 3 projects
- Ridgeline Therapeutics, Inc.$4.4M · 2 projects
- Panluminate Inc.$4.0M · 5 projects
Funding institutes
- NCI$110.8M · 156
- NIGMS$86.0M · 127
- NIAID$73.2M · 126
- NHLBI$55.2M · 84
- NIDDK$52.8M · 77
- NINDS$48.8M · 51
- NIA$36.2M · 42
- NICHD$23.9M · 34
Activity codes funded
- R44507 records
- R43441 records
- R415 records
- U431 record
Most recent new awards
- Use of an Innovative Pre-Formed Structural Scaffold for Reconstruction of Segmental Bone Loss in a Zygomaticomaxillary Complex Model (opens NIH RePORTER)
Revbio, Inc. · 1R44DE035431-01 · NIDCR · Notice Sep 23, 2026
$1.3MR44
- The Therapeutic Development of a Clinical NR1H3 Antisense Oligonucleotide to Reprogram Microglia into a Neuroprotective State in ALS and FTD (opens NIH RePORTER)
Modulo Bio, Inc. · 1R44NS143633-01A1 · NINDS · Notice Sep 19, 2026
$848KR44
- Phase 2: Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus (opens NIH RePORTER)
Atticus Pharma Inc · 1R44AR087266-01A1 · NIAMS · Notice Sep 19, 2026
$1.0MR44
- Development of OPGx-RDH12 as a gene therapy for RDH12 deficiency associated Leber congenital amaurosis (LCA) (opens NIH RePORTER)
Opus Genetics Inc. · 1R44EY038152-01A1 · NEI · Notice Sep 19, 2026
$1.0MR44
- Rib Fixation for Prevention of Proximal Junctional Kyphosis (PJK) in Adult Spinal Deformity Surgery (opens NIH RePORTER)
Apex Orthopaedic Technologies LLC · 1R43AR085492-01A1 · NIAMS · Notice Sep 19, 2026
$316KR43
- PRMT5 Inhibitors as a Novel Therapy for Anti-VEGF-Sensitive and -Resistant Neovascular Age-Related Macular Degeneration (opens NIH RePORTER)
Eqon Pharmaceuticals, LLC · 1R43EY038150-01A1 · NEI · Notice Sep 18, 2026
$233KR43
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
16 NIH institutes and offices take applications under PA-27-101. Contact the program officer at the institute that fits your research before applying.
- NIH
- NEI · National Eye Institute
- NHLBI · National Heart, Lung, and Blood Institute
- NIA · National Institute on Aging
- NIAAA · National Institute on Alcohol Abuse and Alcoholism
- NIAID · National Institute of Allergy and Infectious Diseases
- NICHD · Eunice Kennedy Shriver National Institute of Child Health and Human Development
- NIDDK · National Institute of Diabetes and Digestive and Kidney Diseases
- NIGMS · National Institute of General Medical Sciences
- NIMH · National Institute of Mental Health
- NINDS · National Institute of Neurological Disorders and Stroke
- NIMHD · National Institute on Minority Health and Health Disparities
- NCATS · National Center for Advancing Translational Sciences
- ORIP
- NCI · National Cancer Institute
- ORWH
Related notices
NIH lists no related notices for PA-27-101 yet.
Award terms
- Application types allowed
- Renewal Phase IIB) Resubmission Phase IIB) Revision Phase IIB) New ONLY allowable when submitting a Phase IIB connected to a Phase II contract) See SF424 R&R) Form for more information. The OER Glossary and the How to Apply – Application Guide provide details on these application types. Only those application types listed here are allowed for the NOFO.
- Award budget
- Total funding support direct costs, indirect costs, fee) may not exceed 30,000,000.00 for Phase IIB Strategic Breakthrough awards.Budget guidelines can vary by participating component and may be at the SBA budgetary limits for Phase II. Total funding support normally may not exceed the guidelines in the table below. Applicants are strongly encouraged to contact program officials prior to…
- Project period
- According to statutory guidelines, award periods must not exceed 4 years for a Phase IIB Strategic Breakthrough award. Applicants are encouraged to propose a project duration period that is reasonable and appropriate for completion of the research project. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PA-24-245.
- Companion NOFOs: PA-27-100, PA-27-102, PAR-27-098.
Other open NOFOs for R44
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.